NASDAQ: CURXCuranex Pharmaceuticals Inc Stock
$0.33+0.02 (+6.45%)
Updated Jun 10, 2026
CURX Price
$0.33
Fair Value Price
$0.18
Market Cap
$9.25M
52 Week Low
$0.26
52 Week High
$9.18
P/E
-1.21x
P/B
1.14x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$7.24M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.04
Operating Cash Flow
-$11M
Beta
1.3
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
CURX Overview
Curanex Pharmaceuticals Inc. is an emerging biopharmaceutical company focused on identifying, advancing, and bringing to market plant-based medicines to address various inflammatory conditions. Their primary drug candidate, Phyto-N, is currently in development for a broad spectrum of health issues, including but not limited to ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, gout, and acne. Established in 1996 and based in Jericho, New York, the company was formerly known as Fordman Pharma Inc. before adopting its current name in November 2023.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CURX's potential to beat the market
- CURX doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
CURX
RankedUnranked of 462
RankedUnranked of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $229.63 | A | |
| $52.58 | A | |
| $15.66 | A |
Be the first to know about important CURX news, forecast changes, insider trades & much more!
CURX News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CURX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CURX ($0.33) is overvalued by 79.67% relative to our estimate of its Fair Value price of $0.18 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
CURX ($0.33) is not significantly undervalued (79.67%) relative to our estimate of its Fair Value price of $0.18 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
CURX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more CURX due diligence checks available for Premium users.
Valuation
CURX fair value
Fair Value of CURX stock based on Discounted Cash Flow (DCF)
Price
$0.33
Fair Value
$0.18
Overvalued by
81.87%
CURX ($0.33) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CURX ($0.33) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CURX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
CURX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.21x
Industry
18.33x
Market
14.77x
CURX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.14x
Industry
4.71x
CURX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CURX's financial health
Profit margin
Revenue
$0.0
Net Income
-$3.2M
Profit Margin
0%
CURX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$8.4M
Liabilities
$332.6k
Debt to equity
0.04
CURX's short-term assets ($8.09M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CURX's short-term assets ($8.09M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CURX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$954.6k
Investing
$0.0
Financing
$0.0
CURX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CURX vs Biotech Stocks
Curanex Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.